What is included in glycoprotein inhibitor therapy for percutaneous coronary intervention (PCI)?

Updated: Nov 27, 2019
  • Author: George A Stouffer, III, MD; Chief Editor: Karlheinz Peter, MD, PhD  more...
  • Print

Glycoprotein inhibitor therapy

  • Abciximab, tirofiban, and eptifibatide have all been shown to reduce ischemic complications in patients undergoing balloon angioplasty and coronary stenting; however, evidence supporting their use was established largely before the use of oral P2Y12 inhibitors; all glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors are associated with an increased risk of bleeding
  • Several studies have failed to show the benefit of “upstream” administration of GPIIb/IIIa inhibitors in the era of dual antiplatelet therapy (DAPT); because GPIIb/IIIa inhibitors increase the risk of bleeding, their routine use before PCI is no longer recommended
  • GPIIb/IIIa inhibitors can be used as an adjunctive therapy at the time of PCI, on an individual basis, for large thrombus burden or inadequate P2Y12 receptor antagonist loading

See Technique and Medication for more detail.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!